% | $
Quotes you view appear here for quick access.

UnitedHealth Group Incorporated Message Board

sam_0534 182 posts  |  Last Activity: Aug 26, 2015 9:53 PM Member since: Feb 8, 1998
  • long term holder here...dont like the action but will just wait....

  • Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR®

    TORONTO, August 5, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA") has reinstated a previously-imposed (and then subsequently rescinded) requirement that the Company’s tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules (the “Product”) will have to meet new conditions for bioequivalence prior to receiving final approval. The strengths affected are 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths of its generic Focalin XR® capsules now in the market are not affected. The new bioequivalence requirements also do not apply to any of the Company’s other drug product candidate applications for commercial approval now pending with the FDA.

    To briefly summarize the relevant correspondence from the FDA on this matter:

    · In November 2013, the FDA granted the Company tentative approvals for the 5 mg, 10 mg, 20 mg, and 40 mg strengths of its generic Focalin XR®.
    · In June 2015, the FDA required that the Company demonstrate bioequivalence with Focalin XR® for the 40 mg strength, under new bioequivalence criteria, as a basis for the approval of each of the affected strengths.
    · In July 2015, the FDA rescinded its June 2015 requirement that the Company demonstrate bioequivalence with Focalin XR® for the 40 mg strength, under new bioequivalence criteria, as a basis for the approval of each of the affected strengths.
    · The FDA has now reinstated the requirement that the Company demonstrate bioequivalence with Focalin XR® for the 40 mg strength, under new bioequivalence criteria, as a basis for the approval of each of the affected strengths. More specifically, in reverting to the requirement for a demonstration of bio-equivalence under new criteria, the FDA stated “Upon review, we have concluded that our rescission was issued in error.”

    "We are, of course, disappointed by this unexpected action by the FDA. We remain committed in our efforts to achieve final approval for each of the affected strengths," stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics.

    The Company intends to consider and pursue appropriate courses of action towards achieving final approval for each of the affected strengths. There can be no assurance that the new conditions can be successfully met, or that the affected strengths of the Product will be granted final FDA approval or sold commercially.

  • long term holders will wait for more good news...then the stock can go up again..

    Sentiment: Buy

  • Reply to

    yes! Standup comedian GreGOrI03 is back

    by declaes Aug 4, 2015 11:01 AM
    sam_0534 sam_0534 Aug 4, 2015 12:43 PM Flag

    why do you engage him??????? he needs the attention you keep giving him.. very foolish...put him on IGNORE as you clutter the board with nonsense..

  • * Funds managed by Franklin Resources Inc(BEN), Blackstone Group LP(BX) and Oaktree Capital Group LLC(OAK) , among others, are facing paper losses on substantial investments this year in exploration-and-production companies. The sector is coming under further pressure as oil prices have turned downward again, dropping below $46 a barrel in New York to a four-month low

    Sentiment: Buy

  • sam_0534 sam_0534 Aug 3, 2015 2:32 PM Flag

    well you little sheep keep clogging up this site.. the market is with it..

  • Reply to

    BX Continues to Roll Over, AGAIN ~

    by the_professional_trader Aug 3, 2015 10:46 AM
    sam_0534 sam_0534 Aug 3, 2015 1:26 PM Flag

    why are you engaging him???? go post your uselsss posts somewhere else...should put all worthless polsters on IGNORE and will do if this continues..

  • Reply to


    by m56bm Aug 3, 2015 8:51 AM
    sam_0534 sam_0534 Aug 3, 2015 11:07 AM Flag

    payout is in my Fidelity account this morning...enjoy :)appears to be invested around 39.15

  • as others know here, long time investor..was a stock broker with E..F. Hutton after being a rocket engineer with Rocketdyne after college UVA.....Dont need to be a PT :).. here are my trades :)...but not dumb enough to trade....9/23/2012 at 14.56, 9/30/2012 at 14.27. 6/5/2103 at $21.42, 6/7/2013 at 21.28, finally 4/4/2014 at $29.20 , 4/30/2014 at $28.03... 3,000 shares in total and not including great payouts!!!!!..... Didnt need a PT to tell me what to do.. Been around a long time and the traders never tell you of all their BAD advise..put them on I do... as noted I did sell 500 BX at 39.50 or so before the runup to new highs as I am prudent and was way over weighted with I have liked this stock a lot

  • may be overshadowing the good news...

  • Avintiv, which changed its name from PGI Specialty Materials Inc last month, was bought by Blackstone Group(BX) in 2010 for $326.2 million in cash from private equity firm MatlinPatterson in 2010.

  • sam_0534 sam_0534 Jul 31, 2015 10:28 AM Flag

    cs to buy Blackstone-owned Avintiv for $2.45 billion
    REUTERS 5:53 AM ET 7/31/2015
    Symbol Last Price Change
    BERY 33.13up -0.23 (-0.69%)
    BX 39.3299up +0.0399 (+0.1%)
    QUOTES AS OF 10:21:17 AM ET 07/31/2015

    (Reuters) - Plastic packaging products maker Berry Plastics Group Inc(BERY) said it would buy Avintiv Inc, which makes materials used in products ranging from diapers to disinfectant wipes, for about $2.45 billion in cash from Blackstone Group LP(BX) .

    Berry Plastics (BERY), which makes products such as duct tapes, spray adhesives and food wrap films, said it would buy Avintiv on a debt-free, cash-free basis.

    Berry Plastics' (BERY) shares rose nearly 2 percent to $34 in trading before the bell on Friday.

    Avintiv, which changed its name from PGI Specialty Materials Inc last month, was bought by Blackstone Group(BX) in 2010 for $326.2 million in cash from private equity firm MatlinPatterson in 2010.

    The company, as PGI, filed for an initial public offering in February. At that time the company said its net loss had nearly tripled to about $97 million in the nine months ended Sept. 27, while sales rose 2.2 percent to $1.5 billion.

    Avintiv's specialty materials are also used in feminine hygiene products, face masks and surgical gowns and its customers include Procter & Gamble Co , Kimberly-Clark Corp and Cardinal Health Inc .

    Avintiv has 23 locations in 14 countries and supplies to many of the consumer and industrial product manufacturers that Berry Plastics(BERY) supplies to, Berry Plastics(BERY) said.

    Berry Plastics (BERY) said it expects the deal to add to its earnings and free cash flow and that it had secured debt financing to fund the deal.

    The company expects the deal to close by the end of this year.

    Berry Plastics' (BERY) financial advisers are Credit Suisse and Barclays, while Bryan Cave is its legal adviser. Citi and BofA Merrill Lynch were Avintiv and Blackstone's financial advisers and Simpson Thatcher & Bartlett LLP is their legal adviser.

  • sam_0534 by sam_0534 Jul 30, 2015 2:03 PM Flag

    has some effect on BX today I think

  • Reply to

    When is spinoff to occur?

    by naveeny1974 Jul 30, 2015 12:13 PM
    sam_0534 sam_0534 Jul 30, 2015 12:27 PM Flag

    dont think this will be a factor for BX.. just my opinion...

  • sam_0534 by sam_0534 Jul 30, 2015 10:21 AM Flag

    Goldman Sachs is securitising a loan to Blackstone backed by commercial real estate across the UK, highlighting a growing role for non-banks in a market that has struggled for traction in recent years.
    Securitisation involves taking loans — in this case for the purchase of commercial real estate — and packaging them into bonds, which can then be sold on to investors.

    Sentiment: Buy

  • I will wait for more good news....

    Sentiment: Strong Buy

  • NXP agreed in March to buy Freescale for $11.8 billion in cash and stock, excluding debt. To ease antitrust concerns, NXP sold an overlapping radio frequency amplifier business for $1.8 billion in May to China's state-owned Jianguang Asset Management. Both deals are expected to close later this year.

    The combination of NXP and Freescale will control about 13 percent of a $26 billion global auto electronics market, ahead of Renesas of Japan and Infineon of Germany.

  • Reply to


    by samsa1 Jul 29, 2015 7:33 AM
    sam_0534 sam_0534 Jul 29, 2015 3:54 PM Flag

    guess we need more news to get this stock some action...patient investor here.

    Sentiment: Strong Buy

  • All BX holdings have taken a hit.. BX was very smart to sell a lot of holdings when they were at their highs....Now will see what will dependent... BXMT is doing well.. my good income stock...

  • sam_0534 by sam_0534 Jul 28, 2015 12:10 AM Flag

    QUOTES AS OF 04:03:37 PM ET 07/27/2015
    When Blackstone Group LP's(BX) top executives learned last week that they were losing their longtime chief financial officer, they eschewed a lengthy search and went with one of their most-tenured deal makers.

    The world's largest private-equity firm said last week that Michael Chae would become its finance chief next month when Laurence Tosi, Blackstone's CFO since 2008, leaves for the same role at Airbnb Inc.

    Leaders at Blackstone, which manages roughly $333 billion on behalf of pensions, endowments and wealthy individuals, decided the company's CFO should be someone who could potentially run the firm, and that anyone in that position must have an investing background, according to people familiar with the hire.

    In Mr. Chae, 46 years old, the firm chose one of its most experienced deal makers and trouble shooters. He joined Blackstone in 1997, before the global firm—housed then in a single Manhattan office—even disclosed its assets under management.

    Becoming CFO "represents a natural progression" of his career at Blackstone, Mr. Chae said in an interview Monday. " Having worked across our businesses and regions as an investor, to be able to bring that experience and knowledge to driving the operations of the firm as a whole is an exciting opportunity," he said.

    Mr. Chae played a central role in some of the firm's largest and most lucrative private-equity investments, including those involving arts-and-crafts retailer Michaels Companies Inc., hotelier Hilton Worldwide Holdings Inc. and television-ratings firm Nielsen NV.

    "His investing background is an extremely helpful element to his credibility as a CFO," said John Waldron, co-head of investment banking at Goldman

    Sentiment: Buy

117.77+4.31(+3.80%)Aug 27 4:00 PMEDT